Global lung cancer therapeutics market is expected to generate around USD 42.24 billion by 2025, growing at a CAGR of around 13.2% between 2019 and 2025. Cancer is a disease caused by an uncontrolled division of abnormal cells in a part of the body. These extra cells slowly gather together to form a tissue mass called a tumor.
Lung Cancer Therapeutics Market
The report covers a forecast and an analysis of the lung cancer therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes the drivers and restraints of the lung cancer therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the lung cancer therapeutics market on a global and regional level.
In order to give the users of this report a comprehensive view of the lung cancer therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides a company market share analysis to give a broader overview of the key players in the lung cancer therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the lung cancer therapeutics market on a global and regional basis.
The global lung cancer therapeutics market is segmented based on cancer type, treatment, drug class, end-user, distribution channel, and region. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Some key players in the lung cancer therapeutics market are Hoffmann-La Roche, Eli Lilly and Company, Sanofi-Aventis, Pfizer, Celgene Corporation, GlaxoSmithKline, Boehringer Ingelheim, Agennix, AstraZeneca, and Merck & Co.
This report segments the global Lung cancer therapeutics market into: